Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ • Healthcare
Last close at November 20, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, Amneal Pharmaceuticals, Inc. currently loses $1.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Amneal Pharmaceuticals topped consensus on both the top and bottom line in the second fiscal quarter of 2026, reported July 30, 2026, with adjusted EPS of $0.30 topping the $0.22 estimate (+35%) and revenue of $796.2 million topping the $768.2 million estimate (+3.6%). Revenue rose ~10% to about $796.2 million (up from roughly $724.5 million a year ago) across its Generics, Specialty, and AvKARE businesses, while profitability showed up in margins with gross margin at 42.0% and operating margin at 18.3%. Gross profit came in at about $334.5 million and operating income was roughly $146.0 million, and net income surged about 157% year over year to around $57.7 million (up from roughly $22.4 million a year ago). Cash generation was weaker in the period, with negative operating cash flow of about $19.3 million. For the next period, consensus calls for EPS of $0.24 on revenue of $814.0 million.
About Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) develops, makes, and sells generic and branded medicines in the healthcare sector, with additional distribution of medical supplies and related services. Across its pharmaceutical manufacturing and supply businesses, Amneal generated $3.0 billion of revenue in FY2025.
Today's Snapshot
AMRX closed 1.3% lower at 21.12, while its sector was flat. AMRX closed within 4.6% of its 52-week high of 22.13. Amneal Pharmaceuticals won FDA approval for oxcarbazepine, a seizure medicine.
Trading Volume
Below 10d avg (2.0M)
1.6M
vs S&P 500 Today
Outperforming Market
+2.23%
Updated: November 20, 2026 at 21:12 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$16.75 - $21.24Buy
- RSI (14)53.67Neutral
- Stochastic %K (14, 3, 3)78.56Neutral
- MACD Level (12, 26)0.39Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.